Literature DB >> 18272812

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.

Kiavash Movahedi1, Martin Guilliams, Jan Van den Bossche, Rafael Van den Bergh, Conny Gysemans, Alain Beschin, Patrick De Baetselier, Jo A Van Ginderachter.   

Abstract

The induction of CD11b(+)Gr-1(+) myeloid-derived suppressor cells (MDSCs) is an important immune-evading mechanism used by tumors. However, the exact nature and function of MDSCs remain elusive, especially because they constitute a heterogeneous population that has not yet been clearly defined. Here, we identified 2 distinct MDSC subfractions with clear morphologic, molecular, and functional differences. These fractions consisted of either mononuclear cells (MO-MDSCs), resembling inflammatory monocytes, or low-density polymorphonuclear cells (PMN-MDSCs), akin to immature neutrophils. Interestingly, both MO-MDSCs and PMN-MDSCs suppressed antigen-specific T-cell responses, albeit using distinct effector molecules and signaling pathways. Blocking IFN-gamma or disrupting STAT1 partially impaired suppression by MO-MDSCs, for which nitric oxide (NO) was one of the mediators. In contrast, while IFN-gamma was strictly required for the suppressor function of PMN-MDSCs, this did not rely on STAT1 signaling or NO production. Finally, MO-MDSCs were shown to be potential precursors of highly antiproliferative NO-producing mature macrophages. However, distinct tumors differentially regulated this inherent MO-MDSC differentiation program, indicating that this phenomenon was tumor driven. Overall, our data refine tumor-induced MDSC functions by uncovering mechanistically distinct MDSC subpopulations, potentially relevant for MDSC-targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18272812     DOI: 10.1182/blood-2007-07-099226

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  530 in total

1.  Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.

Authors:  Benedetto Farsaci; Jack P Higgins; James W Hodge
Journal:  Int J Cancer       Date:  2011-08-08       Impact factor: 7.396

Review 2.  TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.

Authors:  Li Yang; Yanli Pang; Harold L Moses
Journal:  Trends Immunol       Date:  2010-06-01       Impact factor: 16.687

3.  Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.

Authors:  Karen M Kaluza; Jill M Thompson; Timothy J Kottke; Heather C Flynn Gilmer; Darlene L Knutson; Richard G Vile
Journal:  Int J Cancer       Date:  2011-11-30       Impact factor: 7.396

Review 4.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

Review 5.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

Review 6.  Myeloid-derived suppressor cells in transplantation and cancer.

Authors:  Jordi C Ochando; Shu Hsia Chen
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

7.  Stromal-derived IL-6 alters the balance of myeloerythroid progenitors during Toxoplasma gondii infection.

Authors:  David B Chou; Brian Sworder; Nicolas Bouladoux; Cindy N Roy; Amiko M Uchida; Michael Grigg; Pamela G Robey; Yasmine Belkaid
Journal:  J Leukoc Biol       Date:  2012-04-09       Impact factor: 4.962

8.  Mouse CD11b+Gr-1+ myeloid cells can promote Th17 cell differentiation and experimental autoimmune encephalomyelitis.

Authors:  Huanfa Yi; Chunqing Guo; Xiaofei Yu; Daming Zuo; Xiang-Yang Wang
Journal:  J Immunol       Date:  2012-10-03       Impact factor: 5.422

9.  In vivo ablation of plasmacytoid dendritic cells inhibits autoimmunity through expansion of myeloid-derived suppressor cells.

Authors:  Marianna Ioannou; Themis Alissafi; Louis Boon; Dimitrios Boumpas; Panayotis Verginis
Journal:  J Immunol       Date:  2013-02-04       Impact factor: 5.422

10.  Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.

Authors:  Güllü Topal Görgün; Gregory Whitehill; Jennifer L Anderson; Teru Hideshima; Craig Maguire; Jacob Laubach; Noopur Raje; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.